Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, MeiraGTx Holdings's enterprise value is €1,060.59 Mil.
MeiraGTx Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €-82.76 Mil. Therefore, MeiraGTx Holdings's EV-to-EBITDA for today is -12.81.
The historical rank and industry rank for MeiraGTx Holdings's EV-to-EBITDA or its related term are showing as below:
FRA:328'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.12 Med: -5.68 Max: -1.85
Current: -12.76
During the past 10 years, the highest EV-to-EBITDA of MeiraGTx Holdings was -1.85. The lowest was -13.12. And the median was -5.68.
FRA:328's EV-to-EBITDA is ranked worse than 100% of 398
companies
in the Biotechnology industry
Industry Median: 13.395
vs FRA:328: -12.76
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MeiraGTx Holdings's PE Ratio (TTM) for today is calculated as:
MeiraGTx Holdings's share price for today is €11.10.
MeiraGTx Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.275.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for MeiraGTx Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:328 vs CRVS, WVE, FBRX: EV-to-EBITDA Comparison
For the Biotechnology subindustry, MeiraGTx Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MeiraGTx Holdings EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MeiraGTx Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where MeiraGTx Holdings's EV-to-EBITDA falls into.
MeiraGTx Holdings's current Enterprise Value is €1,060.59 Mil.
MeiraGTx Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-82.76 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MeiraGTx Holdings (FRA:328) has a EV-to-EBITDA of -12.81 as of Aug. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on MeiraGTx Holdings. According to the industry distribution chart, MeiraGTx Holdings ranks #999999 out of 398 companies in the Biotechnology industry.
Is MeiraGTx Holdings' EV-to-EBITDA too high?
MeiraGTx Holdings' current EV-to-EBITDA is -12.81. Based on the distribution chart, MeiraGTx Holdings ranks #999999 out of 398 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MeiraGTx Holdings has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MeiraGTx Holdings' EV-to-EBITDA compare to CRVS and WVE?
According to the Biotechnology industry distribution chart, MeiraGTx Holdings ranks #999999 out of 398 companies for EV-to-EBITDA. This places MeiraGTx Holdings in the lower half of its industry. The industry median EV-to-EBITDA is 13.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.40, based on 398 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on MeiraGTx Holdings. For the Biotechnology industry, the median EV-to-EBITDA is 13.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MeiraGTx Holdings's current EV-to-EBITDA is -12.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeiraGTx Holdings stock overvalued right now?
Based on GuruFocus' analysis, MeiraGTx Holdings (FRA:328) is currently considered Possible Value Trap. The stock's GF Value™ is €20.72, compared to a current price of €11.10 — trading 46.4% below its estimated fair value. The current EV-to-EBITDA is -12.81. MeiraGTx Holdings' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For MeiraGTx Holdings (FRA:328), the current EV-to-EBITDA is -12.81 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MeiraGTx Holdings (FRA:328) Overvalued in 2026?
Based on GuruFocus' analysis, MeiraGTx Holdings stock appears to be undervalued.
The current stock price of €11.10 is trading 46.4% below its estimated GF Value™ of €20.72.
GuruFocus considers MeiraGTx Holdings to be Possible Value Trap.
Key valuation signals for FRA:328:
EV-to-EBITDA: -12.81
GF Value™: €20.72 vs. price of €11.10 (46.4% below fair value)
No single metric tells the full story. See the FRA:328 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
51GF Score
Get the complete analysis for FRA:328
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:328 has been successfully added to your 
